WEBINAR – How to Bring Regenerative Therapies to Market: The Science, the FDA, and the Business Reality
Learn from Dr. Bruder's decades of experience helping over 800 regenerative therapies get to the bedside.
Most regenerative medicine companies underestimate the complexity of bringing a therapy to market in the USA.
In this Regen Report webinar, Dr. Scott Bruder, founder of Bruder Consulting & Venture Group, shares hard-earned insights from helping more than 800 regenerative and orthobiologic product projects reach the bedside.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
If you don’t know Dr. Scott Bruder, he was the 2nd employee at the late Dr. Arnold Caplan’s Osiris Therapeutics, leading their technology lab. He went on to be the Worldwide VP of Johnson & Johnson Regenerative Therapeutics, and Chief Medical & Scientific Officer at Stryker.
He’s also a physician and now helps companies bring regenerative therapies to market through his consulting group.
Drawing on decades of experience bridging science, regulation, and business strategy, Dr. Bruder explains what truly drives timelines and costs in product development, from preclinical validation and FDA designation to reimbursement and market adoption.
The session will help you interpret the FDA’s 361 vs. 351 HCT/P framework, why “minimal manipulation” is so misunderstood, and what successful companies do differently to reach commercialization.
Whether you’re advancing an early-stage cell therapy, planning your first IND, or evaluating market pathways for an orthobiologic device, this session provides a clear look at the realities—and opportunities—of regenerative product development in 2025.
Register below to watch the free webinar!
Similar stories
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
Wolwo Bio Subsidiary Receives Chinese Trial Authorization for Umbilical Cord Mesenchymal Stem Cell Therapy for Sepsis
YiPSCELL Nabs $8M for iPSC-Derived Cartilage Regeneration
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell TherapyEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-Demand
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
